Is Indivior Pharmaceuticals, Inc. (INDV) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 9.3% / 30% | 7.9% / 30% | 6.3% / 30% | 1.94% / 5% | ✓ HALAL |
| DJIM | 9.3% / 33% | 7.9% / 33% | 6.3% / 33% | 1.94% / 5% | ✓ HALAL |
| MSCI | 28.4% / 33% | 24.3% / 33% | 19.3% / 33% | 1.94% / 5% | ✓ HALAL |
| S&P | 9.3% / 33% | 7.9% / 33% | 6.3% / 33% | 1.94% / 5% | ✓ HALAL |
| FTSE | 28.4% / 33% | 24.3% / 33% | 19.3% / 50% | 1.94% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 84.0% | |
| Operating Margin | 37.2% | |
| Net Margin | 16.9% | |
| Return on Assets (ROA) | 19.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$27M |
| Free Cash Flow | -$94M |
| Total Debt | $351M |
| Current Ratio | 0.7 |
| Total Assets | $1.2B |
Price & Trading
| Last Close | $29.95 |
| 50-Day MA | $32.76 |
| 200-Day MA | $27.15 |
| Avg Volume | 2.4M |
| Beta | 1.2 |
|
52-Week Range
$8.64
| |
About Indivior Pharmaceuticals, Inc. (INDV)
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Purification Calculator
As a halal stock with 1.94% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Indivior Pharmaceuticals, Inc. (INDV) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Indivior Pharmaceuticals, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Indivior Pharmaceuticals, Inc.'s debt ratio?
Indivior Pharmaceuticals, Inc.'s debt ratio is 9.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 28.4%.
Does Indivior Pharmaceuticals, Inc. require dividend purification?
Yes, Indivior Pharmaceuticals, Inc. has an impermissible income ratio of 1.94%, which means 1.94% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Indivior Pharmaceuticals, Inc.'s key financial metrics?
Indivior Pharmaceuticals, Inc. has a market capitalization of $3.6B, trailing P/E ratio of 17.7, and revenue of $1.2B. The company maintains a gross margin of 84.0% and a net margin of 16.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.